These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11544321)

  • 1. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides.
    Gursel I; Gursel M; Ishii KJ; Klinman DM
    J Immunol; 2001 Sep; 167(6):3324-8. PubMed ID: 11544321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
    de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
    Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N; Mukherjee S; Das L; Das PK
    Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection.
    Ito S; Ishii KJ; Gursel M; Shirotra H; Ihata A; Klinman DM
    J Immunol; 2005 Jan; 174(2):777-82. PubMed ID: 15634898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
    BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes.
    Li WM; Bally MB; Schutze-Redelmeier MP
    Vaccine; 2001 Oct; 20(1-2):148-57. PubMed ID: 11567759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.
    Mui B; Raney SG; Semple SC; Hope MJ
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1185-92. PubMed ID: 11504819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination.
    Bal SM; Hortensius S; Ding Z; Jiskoot W; Bouwstra JA
    Vaccine; 2011 Jan; 29(5):1045-52. PubMed ID: 21129393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.
    Jaafari MR; Badiee A; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
    Vaccine; 2007 Aug; 25(32):6107-17. PubMed ID: 17629372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides.
    Wilson JT; Keller S; Manganiello MJ; Cheng C; Lee CC; Opara C; Convertine A; Stayton PS
    ACS Nano; 2013 May; 7(5):3912-25. PubMed ID: 23590591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes.
    Li WM; Dragowska WH; Bally MB; Schutze-Redelmeier MP
    Vaccine; 2003 Jul; 21(23):3319-29. PubMed ID: 12804863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovative strategies for co-delivering antigens and CpG oligonucleotides.
    Krishnamachari Y; Salem AK
    Adv Drug Deliv Rev; 2009 Mar; 61(3):205-17. PubMed ID: 19272328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
    Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
    Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein.
    Rao M; Matyas GR; Vancott TC; Birx DL; Alving CR
    Immunol Cell Biol; 2004 Oct; 82(5):523-30. PubMed ID: 15479438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles.
    Wilson KD; Raney SG; Sekirov L; Chikh G; deJong SD; Cullis PR; Tam YK
    Int Immunopharmacol; 2007 Aug; 7(8):1064-75. PubMed ID: 17570323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
    Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
    J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivo.
    Hamm S; Heit A; Koffler M; Huster KM; Akira S; Busch DH; Wagner H; Bauer S
    Int Immunol; 2007 Mar; 19(3):297-304. PubMed ID: 17289655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cationic liposomes extend the immunostimulatory effect of CpG oligodeoxynucleotide against Burkholderia pseudomallei infection in BALB/c mice.
    Puangpetch A; Anderson R; Huang YY; Sermswan RW; Chaicumpa W; Sirisinha S; Wongratanacheewin S
    Clin Vaccine Immunol; 2012 May; 19(5):675-83. PubMed ID: 22441390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
    McCluskie MJ; Weeratna RD; Davis HL
    Mol Med; 2000 Oct; 6(10):867-77. PubMed ID: 11126201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant activity of CpG-ODN formulated as a liquid crystal.
    Sánchez Vallecillo MF; Ullio Gamboa GV; Palma SD; Harman MF; Chiodetti AL; Morón G; Allemandi DA; Pistoresi-Palencia MC; Maletto BA
    Biomaterials; 2014 Mar; 35(8):2529-42. PubMed ID: 24382332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.